Clonal Hematopoiesis in Late-Stage Non–Small-Cell Lung Cancer and Its Impact on Targeted Panel Next-Generation Sequencing
Stephanie J. Yaung, Frederike Fuhlbrück, Maureen Peterson et al. · JCO Precision Oncology · 2020
PURPOSE: Somatic mutations derived from the expansion of clonal populations of blood cells (clonal hematopoiesis of indeterminate potential, or CHIP) may be detected in sequencing of cell-free DNA (cfDNA) samples. We evaluated the potential implications of CHIP in targeted sequencing of plasma samples using matched peripheral blood mononuclear cells (PBMCs) from patients with lung cancer to identify potential CHIP-associated mutations. MATERIALS AND METHODS: A total of 332 plasma and corresponding PBMC samples were collected predose, cycle 1 day 1 (C1D1), from the randomized, phase III study (OAK) comparing atezolizumab versus docetaxel in previously treated patients with non-small-cell lung cancer (NSCLC). The samples were analyzed with the AVENIO ctDNA Surveillance Kit (for research use only; not for use in diagnostic procedures), a 198-kb next-generation sequencing panel targeting cancer-related genes. CHIP variants were assessed by analyzing both plasma and PBMC sequencing data. RESULTS: was the most frequently mutated gene. Furthermore, the allele frequency was less variable over time for CHIP variants than for tumor-derived variants. CONCLUSION: CHIP-derived mutations are present in late-stage NSCLC. However, not all plasma samples had CHIP mutations detected with targeted panel sequencing. Paired PBMC sequencing analysis may be needed to remove CHIP variants for comprehensive genomic profiling using plasma samples to identify true somatic mutations.
Cited by 43 works. doi:10.1200/po.20.00046
Authors
- Stephanie J. Yaung
- Frederike Fuhlbrück
- Maureen Peterson
- Wei Zou
- John F. Palma
- Namrata S. Patil
- Yuqiu Jiang
References
- A global reference for human genetic variation
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
- Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
- COSMIC: exploring the world's knowledge of somatic mutations in human cancer
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
- Age-related mutations associated with clonal hematopoietic expansion and malignancies
- Liquid biopsies come of age: towards implementation of circulating tumour DNA
- Integrated digital error suppression for improved detection of circulating tumor DNA
- Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer